Divi's Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+12.8%+19.3%+1.0%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+15.9%+34.6%−6.9%
+16.1%+40.4%−9.8%
+17.2%+36.9%−12.3%
+17.2%+36.9%−12.3%
+18.3%+9.5%+7.1%
+12.0%+10.3%+6.3%
+65.6%+31.1%−48.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DIVISLAB₹9,664.00

Divi's Laboratories Ltd.

· Pharma & Health
₹ CrorePeersLAURUSLABSCOHANCEGLANDTORNTPHARMZYDUSLIFEMAXHEALTHDRREDDYCIPLAMcap ₹2.56L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+1.0+19.3+12.8—
EBITDA Growth—-6.9+34.6+15.9—
EBIT Growth—-9.8+40.4+16.1—
Net Income Growth—-12.3+36.9+17.2—
EPS Growth—-12.3+36.9+17.2—
Total Assets Growth—+7.1+9.5+18.3—
Total Equity Growth—+6.3+10.3+12.0—
Cash from Operations Growth—-48.7+31.1+65.6—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.